The Role of High-Risk Human Papilloma Virus Testing in the Surveillance of Cervical Cancer After Treatment.
暂无分享,去创建一个
R. M. Austin | S. Beriwal | J. Kelley | R. Edwards | A. Olawaiye | P. Sukumvanich | J. Comerci | Jeff F. Lin | T. Beck | Miao Yu | Robert P. Edwards | Miao Crystal Yu | R. Marshall Austin
[1] J. Berkhof,et al. Posttreatment Assessment of Women at Risk of Developing High-Grade Cervical Disease: Proposal for New Guidelines Based on Data From The Netherlands , 2014, Journal of lower genital tract disease.
[2] M. Schiffman,et al. Five-Year Risk of Recurrence After Treatment of CIN 2, CIN 3, or AIS: Performance of HPV and Pap Cotesting in Posttreatment Management , 2013, Journal of lower genital tract disease.
[3] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[4] J. Palmgren,et al. Prospective Study of HPV16 Viral Load and Risk of In Situ and Invasive Squamous Cervical Cancer , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[5] Phanida Jarruwale,et al. Human papillomavirus infection following radiation therapy or concurrent chemoradiation for invasive cervical cancer. , 2012, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[6] B. Goff,et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. , 2011, American journal of obstetrics and gynecology.
[7] N. Muñoz,et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.
[8] H. Cubie,et al. High-Risk HPV Genotyping in the Follow-Up of Women Treated Conservatively for Microinvasive Cervical Cancer , 2009, International Journal of Gynecologic Cancer.
[9] T. Oliver,et al. Follow-up for women after treatment for cervical cancer: a systematic review. , 2009, Gynecologic oncology.
[10] M. Poljak,et al. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. , 2009, Acta dermatovenerologica Alpina, Pannonica, et Adriatica.
[11] W. Kang,et al. Comparison of the Hybrid Capture II Assay With the Human Papillomavirus DNA Chip Test for the Detection of High-Grade Cervical Lesions , 2009, International Journal of Gynecologic Cancer.
[12] Guifang Yu,et al. Associations of high-risk HPV types and viral load with cervical cancer in China. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[13] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[14] P. Maisonneuve,et al. Carcinoma of the cervix uteri , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[15] J. Cuzick,et al. Detection of high‐risk HPV types by the hybrid capture 2 test , 2001, Journal of medical virology.
[16] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[17] J. Pfisterer,et al. Human papillomavirus DNA in locally recurrent cervical cancer. , 1994, Gynecologic oncology.
[18] R. Holloway,et al. Identification of human papillomavirus type 16 in primary and recurrent cervical cancer following radiation therapy. , 1991, Gynecologic oncology.
[19] M. Schiffman,et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. , 2012, American journal of clinical pathology.
[20] A. Jemal,et al. Global Cancer Statistics , 2011 .